Loading
M7437 / Advanced Solid Tumors · Phase 1 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 first-in-human trial registration for M7437, an anti-Ly6E exatecan antibody-drug conjugate, in advanced solid tumors. The study is currently recruiting; no efficacy or safety results have been reported. Clinical interpretation is not possible until results are posted.
Phase 1, Interventional, Non Randomized, Sequential, Open label, Other purpose. Advanced Solid Tumors; age from 18 Years. Intervention: Part 1: Dose-escalation Cohort; Part 2: Dose-Expansion Cohort. n = 138. 9 sites across 4 countries.
This is a Phase 1 first-in-human trial registration for M7437, an anti-Ly6E exatecan antibody-drug conjugate, in advanced solid tumors. The study is currently recruiting; no efficacy or safety results have been reported. Clinical interpretation is not possible until results are posted.
Study is currently recruiting; no safety, tolerability, pharmacokinetic, or clinical activity data are available.
The source did not state who this applies to in practice.
This is a first-in-human Phase 1 trial registration with no results posted; the study is actively recruiting and has not yet reported safety, tolerability, or efficacy outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07360314). This is a study registration, not published results. Lead sponsor: EMD Serono Research & Development Institute, Inc.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 138 participants (ESTIMATED). Conditions: Advanced Solid Tumors. Interventions: DRUG: M7437; DRUG: M7437. Primary outcome measures: Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs) , DLT period is 21 days (cycle 1); Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs) , Up to end of Part 1 of study (approximately 1 year 8 months). Brief summary: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.